NYSE American - Delayed Quote USD

NanoViricides, Inc. (NNVC)

1.1500 +0.0100 (+0.88%)
At close: 4:00 PM EDT
1.2000 +0.05 (+4.35%)
After hours: 6:01 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Anil R. Diwan Ph.D. Executive Chairman, President, CEO & Secretary 400k -- 1959
Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA Chief Financial Officer 129.6k -- 1959
Dr. Randall W. Barton Ph.D. Chief Scientific Officer -- -- 1947

NanoViricides, Inc.

1 Controls Drive
Shelton, CT 06484
United States
203 937 6137 https://www.nanoviricides.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
7

Description

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Corporate Governance

NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
NanoViricides, Inc. Earnings Call

Related Tickers

CHRO Chromocell Therapeutics Corporation
1.5700
+0.64%
 
INDP Indaptus Therapeutics, Inc.
2.3500
-5.62%
 
NBTX Nanobiotix S.A.
5.90
+1.72%
 
EDSA Edesa Biotech, Inc.
4.3100
-2.93%
 
IMNN Imunon, Inc.
1.3000
-2.26%
 
INAB IN8bio, Inc.
1.0600
+1.92%
 
STRO Sutro Biopharma, Inc.
3.4700
-6.72%
 
CTNM Contineum Therapeutics, Inc.
15.93
+0.13%
 
TVGN Tevogen Bio Holdings Inc.
1.5000
-9.09%
 
CANF Can-Fite BioPharma Ltd.
1.9400
-1.52%